secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001759425-24-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data
--------------------------------------------------------------------------------

- Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.
- LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.
- Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.
- LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.
- Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/0001759425-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/mirm-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001759425-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer